The FDA recently announced approval of dupilumab (dupixent), the life-changing medication for children ages 12-17 for the treatment of atopic dermatitis or eczema. Dr. Emma Guttman-Yassky’s research results of phase 3 dupilumab studies in children helped clear the way for the FDA approval.
source
